Eli Lilly: Cost advantages in obesity therapy secure reimbursement prospects for the healthcare system

Zepbound reduces monthly costs for patients aged 55 and older by up to $607. Reduced hospital stays cover Medicare expenses from the sixth month. The study data strengthens Lilly's bargaining position for reimbursement. Profitability through focus on metabolic diseases The business model of Eli Lilly (LLY) is based on therapies in areas such as diabetes and obesity. A central driver is the segment of GLP-1/GIP agonists. Given the increasing prevalence of metabolic diseases, the company benefits from a structural demand trend. Expanding...